WallachBeth Capital Upgrades DepoMed Inc (DEPO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance
November 9, 2015 4:01 PM EST
NEWARK, Calif., Nov. 9, 2015 /PRNewswire/ --Â Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended September 30, 2015.
"Depomed is now one of the top U.S. companies in pain and neurology. Â In the third quarter, the company achieved historic highs in product sales, driven by significant growth in both prescriptions and market share," said Jim Schoeneck, President and CEO of Depomed. "Our new flagship franchise NUCYNTA, which we began promoting in June, led the way with revenue growing 15% over the prior... More
